The past year has seen record investment and deal levels across the Life Sciences sector. Far from stifling investment the pandemic has seemingly turbocharged the system and not just for those actively involved in Covid-19. The UK Life Science innovation field has demonstrated its strengths with R&D, both with successful clinical studies on treatments, surveillance and diagnostics of Covid-19 variants but in non-related areas such as immune-oncology. This has not gone unnoticed by investors with the UK Life Sciences sector seeing a record breaking year of venture investment, successful IPOs and significant M&A deals. With deal values high in the US and the UK demonstrating its value, the panel will discuss what this means for the UK businesses seeking investment, licensing deals and alliances in the US.
One Nucleus Members: Free
Non-Members: £50 +VAT
In association with Fish & Richardson